Targeted lung denervation (TLD) therapy delivered to both lungs was feasible and safe reported in a recent study published in the International Journal of chronic obstructive pulmonary disease. Targeted lung denervation (TLD) is a novel bronchoscopic therapy for patients with chronic obstructive pulmonary disease (COPD) that involves the use of electrical waves to disrupt airway passage nerve transmission. However, there is less evidence for the feasibility and long-term safety of bilateral TLD during a single procedure. In this regard, a recent prospective, multicenter study evaluated 15 patients with moderate-to-severe COPD [forced expiratory volume in 1 s (FEV1): 30%-60%].
According to the study, A total of 15 patients (mean age: 63.2; 47% male,) underwent TLD with a total procedure time of 89 minutes. The total fluoroscopy time was 2.5 minutes. Moreover, all patients met the primary…
